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I.  Context 
 
Stem cells are undifferentiated cells in the human body able to replenish themselves by dividing or capable 
under particular natural or medically-induced circumstances to develop into the more specialized cells 
forming bones, nerves, body tissue, brains, muscles and blood.  Somatic (“adult”) stem cells can be 
extracted from various body parts.  Stem cells are interesting to scientists and physicians for three reasons.  
First, studying stem cells reveals more about the processes of normal and abnormal cell development, 
providing knowledge with potential for treating cancer and birth defects arising from faulty cell division.  
Second, stem cells offer the possibility of regenerative therapy for a range of diseases and conditions 
because they can develop into any body part. The goal is to develop regeneration in other organs where it 
does not occur naturally by using stem cells to develop healthy cells of the affected organ or tissue and 
inject those new cells into patients.  Third, stem cells can be used in therapeutic cloning to correct life-
threatening genetic defects.1 
 
Stem cell research has provoked considerable ethical concern.  Some observers worry that it will lead to 
cloning of humans or producing “designer babies” with traits their parents desire by using in vitro 
fertilization techniques.  While many welcome the prospect of more effective treatments of birth defects or 
diseases, using human embryonic stem cells for such treatments or even in scientific research is very 
controversial.  The embryo must be destroyed to secure its stem cells, and anyone who believes that 
                                                 
1 Good internet sources of basic information on stem cells and stem cell research include www.isscr.org/public produced by the 
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human life begins at the moment sperm fertilizes egg to turn it into an embryo regards destroying embryos 
as committing murder. 
 
Stem cells exist in all humans, and can be derived from adults’, umbilical cords (which are discarded after 
birth), and embryos.  Somatic (“adult”) stem cells were first identified in bone marrow in the 1960s and used 
for treatments of leukemia, aplastic anemia, and some immune system deficiencies.  Bone marrow 
transplants are also used to aid recovery from strong radiation treatments or chemotherapy.  Embryonic 
stem cells were first derived from mouse embryos in 1981, and from human embryos in 1998.  A process 
for “reprogramming” specialized adult cells to resemble stem cells was developed with mice during 2006 
and extended to humans in 2007.  The resulting induced pluripotent stem cells (iPCSs) have inspired 
considerable interest because they would not inspire the same ethical concerns inspired by derivation of 
embryonic stem cells.  However, the methods for “reprogramming” are not yet routine and, because they 
involve use of viruses, may pose significant hazards.  Various types of somatic stem cells have been used 
in certain medical treatments, and may have the advantage of being less likely to trigger rejection since 
they are grown from the patient to be cured, but they are shorter-lived and more difficult to increase through 
cell culture techniques than the embryonic stem cells derived from blastocysts (embryos in their 3rd through 
5th day of development after fertilization).   
 
Excitement generated by the first acquisition of human embryonic stem cells in 1998 spread around the 
world.  In South Korea, where scientists and the government had been attuned to advances in genetics, 
bioscience, and biotechnology since the mid-1980s, there was strong interest in taking up the new 
possibilities.  Four years earlier the South Korean government had adopted an ambitious Plan 2000 
intended to make South Korea one of the leading sites of bioscience and biotechnology research in the 
world.  In 1990, it provided its national Genetics Research Institute with ample facilities in the new Taedok 
Science town just outside Seoul; in 1995 it expanded the Institute and renamed it the Korea Research 
Institute for Bioscience and Biotechnology to better reflect its expanded areas of work.  After 1998 South 
Korean government agencies were eagerly funding research on human embryonic stem cells and on 
somatic cell nuclear transfer (removing the nucleus of an unfertilized egg cell, replacing it with material from 
the nucleus of a specialized body cell, and stimulating this assembled cell divide), both of which promised 
to usher in a new range of medical therapies.  In early 2003, the Ministry of Science and Technology 
reaffirmed its continuing interest by funding a project on xenotransplantation to be carried out by about 184 
researchers in over a dozen Korean universities.2 
 
Koreans became very excited about the therapeutic possibilities of stem cells as scientists suggested that it 
would not be long before stem cell-based treatments of various genetic defects and still-incurable diseases 
would be developed.  Korean business leaders also saw considerable potential for industrial leadership in 
the field based on the apparent strength of local research. 
 
Dr. Hwang Woo-suk, a member of the veterinary faculty at Seoul National University, emerged as one of 
South Korea’s leading stem cell and cloning researchers in 1999 after claiming to have cloned cows.  In 
2002-05 he and several teams of collaborators were pursuing research on human and animal cloning and 
on embryonic stem cells.  The human stem cell research raised three ethical concerns.  The first arose 
from Hwang’s plan to clone human embryos to provide stem cells from which he hoped to make “tailored” 
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or “patient-specific” stem cells.  Stem cells had already been derived from human embryos – “spares” 
remaining in storage at fertility clinics after in vitro fertilization of an egg then implanted into a woman’s 
uterus.  Even this use of embryos had aroused serious controversies in some countries.  Religious 
conservatives and philosophers treating embryos as fully human, and therefore, entitled to complete 
respect of their human identity, condemned using the “spare” embryos as a source of stem cells.  Many 
more people were uneasy about the notion of cloning human embryos for any purpose, including the 
derivation of stem cells.  As Dr. Hwang and his colleagues set to work, 12 countries had already banned all 
forms of human cloning3 and other scientists in South Korea criticized Hwang for pressing forward with 
embryo cloning when the question of its propriety had not been debated or settled.4  The second ethical 
concern arose when other scientists charged in late 2005 that at least two, and possibly as many as five, 
papers published by Hwang and collaborators contained fabricated data.5   The third, which is the subject 
of this case, arose from questions about how Hwang and his collaborators recruited women to donate eggs 
(oocytes) for the research.  This controversy involved basic issues about treatment of human research 
subjects that had been debated at length in many countries.  
 
Concern about protecting humans, whether patients or healthy persons, from abuse by medical 
researchers became acute in the wake of revelations about experiments on prisoners in Nazi concentration 
camps.  The Nuremberg War Crimes Trials resulted in convictions of several of the participating physicians 
of crimes against humanity.6   The detailed revelations of the trial also inspired the earliest internationally 
agreed statement of ethics relating to human subjects, the Nuremberg Code of 1947.  It set forth the 
principles of informed consent, absence of undue influence in securing that consent, humane conditions, 
avoidance of unnecessary pain, and clear scientific benefit.  Continuing abuses, including the deliberate 
infection of unknowing human subjects with serious diseases that had been a central part of the charges 
against the Nazi physicians, were known to medical researchers. 7  In 1964 the World Medical Association 
adopted the first version of the Declaration of Helsinki outlining ethical standards to guide use of human 
subjects in medical research.  General public attention was revived in the USA and other countries during 
1972-73 by extensive newspaper discussion and Congressional Hearings on the Tuskegee Syphilis Study 
(1932-1972).  It involved two clear violations of the Nuremberg Code:  the African-American males selected 
for the study were given incomplete and misleading information about the goals and duration of the 
experiment, and were denied adequate treatment for the disease even after highly effective penicillin cures 
were developed in 1947 so researchers could continue observing the natural course of the disease.8  
                                                 
3R.M. Isasi and B.M. Knoppers, National Regulatory Frameworks regarding Human Cloning for Reproductive and 
Therapeutic/Research Purposes, August 2005 available at http://www.dnapolicy.org/pdf/cloning.pdf (accessed 14 Sept 2009). 
 
4 Letter to the editor by Song Sang-yong, President of the Korean Bioethics Association, and response by Hwang Woo-suk and 
Moon Shen-yong defending their work as conforming with all requirements of South Korean law in Science 305: 944-945 (13 
August 2004).  
 
5Rowan Hooper, “Rise and fall of the stem cell king,” New Scientist 188 (No. 2531/2532):  24 December 2005. 
 
6 George J. Annas and Michael A. Grodin, eds., The Nazi Doctors and the Nuremberg Code: Human Rights in Human 
Experimentation.  New York: 1992; Paul Hoedeman, Hitler or Hippocrates: Medical Experiments and Euthanasia in the Third 
Reich, Ralph de Rijke, trans.  Lewes 1991. 
  
7 Henry K. Beecher, “Ethics and clinical research,” New England Journal of Medicine 274: 1354-1360 (1966). 
 






Reports of severe maltreatment of patients in psychiatric hospitals later in the decade kept the issue in 
view, with later revelations inspiring the World Medical Association to revise the Helsinki Declaration 
several times.  In 2002 when Hwang’s research teams first recruited egg donors, the 2000 revision was the 
most recent statement.  While the Helsinki Declaration was the statement of an international professional 
group, similar standards had been incorporated into national law or regulations governing the conduct of 
medical research on humans in many countries. 
 
South Korean law did not address the question of permissible and impermissible types of genetic research, 
cloning, or stem cell research in 2002, but it did include provisions for protection of human subjects.  
Korean universities and research hospitals were required to have an Institutional Review Board and 
researchers were required to submit their plans for all research using human subjects, a description of how 
they will select human subjects, and copies of the consent forms they intend to use for the IRB’s approval 
before starting their experiments.  South Korean law also required that an IRB include non-researchers, 
specifically “more than one attorney or religious representative, not from the fields of medicine, dentistry, 
oriental medicine, pharmacy, or nursing sciences.”9 
 
Paragraph 1 of the Helsinki Declaration specifies that, “medical research involving human subjects includes 
research on identifiable human material and identifiable data.”  Thus its guidance applies to any form of 
stem cell research that begins with securing stem cells from human body parts or embryos.  The 
Nuremberg Principles and the Helsinki Declaration also cover the process of securing eggs and sperm 
needed to produce embryos since these require human participants.  The stimulation of erection and 
ejaculation needed to secure sperm do not require any drugs or surgery; egg donation involves hormone 
injections and a surgical procedure, so most of the attention devoted to questions of protecting donors has 
focused on the women providing eggs. 
 
The basic surgery for egg donation is minor, and can be performed in a clinic.  The process begins with one 
or more injections of hormones that cause ovaries to “superovulate”—to produce 12-20 eggs per menstrual 
cycle rather than the usual single egg.  The eggs are then gathered from the ovary by follicular aspiration, 
in which a long needle is passed through the vagina into each ovary and eggs removed from the follicles by 
a suction device connected to the needle.  All women who undergo follicular aspiration are given pain 
killers during the procedure and will feel cramping for up to a day afterward.  The hormone injections can 
cause ovarian hyperstimulation syndrome (OHSS), and in the USA some 10% of women undergoing 
follicular aspiration for in vitro fertilization treatments experienced OHSS afterward.  The risk is greater for 
women who are under 35 years old, have high estrogen levels, or have polycystic ovarian syndrome (cysts 
blocking follicles in the ovaries).  The risk is also increased for women receiving injections of human 
chorionic gonadotropin (hCG) to help trigger ovulation, particularly if they receive more than one dose of 
hCG after ovulation.  Risk is much lower among women given fertility drugs taken by mouth.  Mild cases of 
OHSS produce abdominal bloat and discomfort, and water retention weight gain of about 5 pounds; these 
symptoms correct themselves in a few days with rest, ample fluids, and avoidance of stressful activity.  
Severe cases of OHSS produce weight gain of more than 10 pounds, severe abdominal pain and swelling, 
decreased urination, and shortness of breath.  Such cases are usually treated in hospital where the 
woman’s condition can be monitored as excess are removed from abdominal and chest areas and 
intravenous provision of nutritional fluids restores electrolyte balance.  Severe OHSS can lead to life-
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threatening complications: blood clots, kidney failure, electrolyte imbalance, or massive fluid buildup in 
chest and abdomen.10  It can also cause infertility. 
 
The ethical standards for human subjects research most relevant to donors are the requirements for 
voluntary informed consent to the medical procedures involved, high standards of researcher competence, 
and provision of needed treatment for subjects experiencing ill effects.  
 
Both the Nuremberg Code and the Helsinki Declaration gave detailed definitions of the required consent to 
participate.  Article 1 of the Nuremberg Code specified that: 
 
… the person involved should have legal capacity to give consent; should be so situated as to be 
able to exercise free power of choice, without the intervention of any element of force, fraud, 
deceit, duress, over-reaching, or other ulterior form of constraint or coercion; and should have 
sufficient knowledge and comprehension of the elements of the subject matter involved as to 
enable him to make an understanding and enlightened decision. This latter element requires that 
before the acceptance of an affirmative decision by the experimental subject there should be made 
known to him the nature, duration, and purpose of the experiment; the method and means by 
which it is to be conducted; all inconveniences and hazards reasonably to be expected; and the 
effects upon his health or person which may possibly come from his participation in the experiment. 
  
The Helsinki Declaration adopts similar standards.  Paragraph 22 of the 2000 version read: 
 
In any research on human beings, each potential subject must be adequately informed of the aims, 
methods, sources of funding, any possible conflicts of interest, institutional affiliations of the 
researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail.  
The subject should be informed of the right to abstain from participation in the study or to withdraw 
consent at any time without reprisal.  After ensuring that the subject has understood the 
information, the physician should then obtain the subject’s freely- given informed consent, 
preferably in writing.  If the consent cannot be obtained in writing, the non-written consent must be 
formally documented and witnessed. 
 
Paragraph 23 added: 
 
When obtaining informed consent for the research project, the physician should be particularly 
cautious if the subject is in a dependent relationship with the physician or may consent under 
duress.  In that case the informed consent should be obtained by a well-informed physician who is 
not engaged in the investigation and who is completely independent of this relationship.11 
 
                                                 
10 Information on OHHS from the US National Institutes of Health MedlinePlus Medical Encyclopedia at 
http://www.nlm.nih.gov/medlineplus/ency/article/007294.htm (accessed 21 July 2009).  The 10% incidence figure was calculated 
in 2007.  
 
11 Declaration of Helsinki, 2000, available at http://www.mch.org.tw/top_2/IRBWORD/Declaration%20of%20Helsinki.pdf  (The 






Another statement of similar principles widely followed in Korea appears in the International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines 
for Good Clinical Practice (ICH-GCP) adopted in 1997.  The conference is a body consisting of drug 
regulatory agencies in the EU, Japan, and the USA plus pharmaceutical industry representatives; the GCP 
are jointly-established standards for clinical trials.  Following the guidelines means the results data will be 
accepted by EU, Japanese, and US authorities.  As pharmaceutical firms began pursuing trials in more 
countries, cooperating investigators elsewhere were brought within the guidelines, and they diffused 
through researcher communities in other parts of the world.  
 
When the South Korean stem cell research projects began in 2002, scientists around the world generally 
agreed that undergraduate and graduate students, junior members of research teams, and other 
employees over whom researchers have supervisory authority should not be used as donors.  Art Calpan, 
Head of the University of Pennsylvania Center for Bioethics, commented as the scandal broke in May 2004 
that using students or junior members of research teams is bad because “it could certainly look like 
coercion was involved”12 and other scientists expressed similar views.  There was no global consensus on 
whether egg donors could be paid.  Some countries prohibited payment; others allowed small payments as 
compensation for time or travel expenses; others allowed direct payment. 
 
In 2002-03, South Korean law about medical research had several gaps.  The Korean Food and Drug 
Administration oversaw the use of human subjects in commercial research projects, including clinical trials, 
but its authority did not extend to scientific research.  Supervision of scientific research was left to the 
Institutional Review Boards of individual universities or hospitals.  The typical IRB did require human 
subjects to give voluntary, written consent to participate.  Korean regulations banned donations from junior 
members of research teams,13 but did not specifically ban paying donors.  Korean participants in a 
UNESCO-sponsored workshop on bioethics held in Seoul in mid-November 2004 noted that “There are 
currently no special guidelines or regulations on human research other than within the medical field, and 
this deficiency needs to be addressed.  For international research, Korean medical scientists are required 
to observe ICH-GCP.”14 
 
II.  The Controversy 
 
In 2002 when his team began their effort to develop patient-specific stem cell lines by extracting stem cells 
from cloned embryos, Dr. Hwang Woo-suk was one of South Korea’s leading stem cell researchers.  He 
already had a record of considerable research accomplishment, was skilled at organizing teams for large 
projects, and had sufficient international reputation to recruit foreign collaborators.  He was a veterinarian, 
on the Veterinary Faculty at Seoul National University, and therefore not qualified to perform medical 
procedures on humans.  Acquisition of human oocytes for his research was accomplished by various 
                                                 
12 David Cyranoski, “Korea’s stem-cell stars dogged by suspicion of ethical breach.”  Nature 429 p. 3 (6 May 2004). 
 
13 Noted in Kristen Philipkoski, “Jabs, honors for stem-cell expert,” Wired Magazine 16 Nov. 2005.  Available from 
http://www.wired.com/medtech/health/news/2005/11/69596 (accessed 20 July 2009). 
 
14 Quoted from the summary of proceedings of the UNESCO-Korean National Commission for UNESCO workshop on “Ethics 
around the World – Seoul: Towards a Declaration on Universal Norms on Bioethics” 16 November 2006 available at 






physician collaborators at Hanyang University Hospital, MizMedi Women’s Hospital, Hanna Women’s Clinic 
and Chiel General Hospital in Seoul.  
 
Collaborators at Hanyang University Hospital submitted plans for the experiments and for procurement of 
oocytes to its Institutional review Board, which approved them.  Enough oocytes were acquired to begin the 
cloning and stem cell extraction in late 2002- early 2003.  Meanwhile, Hwang and his collaborators also 
worked on other projects, including efforts to clone animals.  Results of the experiments were published in 
leading scientific journals.  Science published his team’s claim to have cloned human embryos in August 
200415 and to have derived patient-specific stem cells in May 2005.16  Nature published his team’s claim to 
have cloned a dog in August 2005.17 
 
Though online supplementary material published with the 2004 paper in Science indicated that volunteers 
were not paid and had provided informed consent on forms detailing how the eggs would be used, rumors 
that two female members of Hwang’s research team had donated eggs and that other donors had been 
paid began to circulate in late 2003.  Science journalists on Nature’s staff made some inquiries and 
published a short comment about the allegations in May 2004.18  Hwang denied the allegations and was 
supported in his denial by members of the Hanyang University Hospital IRB.  However, the controversy did 
not go away.  In late May, Members of the South Korean Bioethics Association called on Hwang to answer 
continuing questions about the egg donors and the sources of his research funding.  Nature printed another 
report about the controversy in its June 3rd issue.19 
 
Public support for Hwang’s research remained high.  Publication of the patient-specific stem cell paper in 
Science had triggered a threefold rise in prices of South Korean biotech stocks.  In late June, the South 
Korean Ministry of Science and Technology honored Hwang with the new title of Supreme Scientist and 
awarded him the equivalent of US$15 million in research support.  An internet “I love Hwang Woo-suk” fan 
club also appeared.  Excitement continued as MgenBio, a Seoul National University-affiliated venture firm 
set up by Hwang and others, announced successful cloning of transgenic pigs expressing human leukocyte 
antigen (HLA)-G, which is thought to improve immune tolerance of humans to transplanted pig tissues.  If 
the antigen had the expected effects, this would permit using pig organs, cells, or tissues in a range of 
disease treatments.20  Korean media reports that the government planned to establish a World Stem Cell 
Hub to be a repository of stem cells were confirmed in October when South Korean President Roh Moo-
hyun authorized allocation of government funds for its establishment at Seoul National University and 
appointed Hwang as its President.   In mid-November, the government indicated that it would provide 11.5 
                                                 
15 Hwang, W.-S. et al. "Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst". Science 303 
(#5664), 1669–1674 (2004). 
 
16 Hwang, W.-S. et al. "Patient-specific embryonic stem cells derived from human SCNT blastocysts" Science 308 (# ), 1777–
1783 (2005). 
 
17 Hwang, W.-S. et al., "Dogs cloned from adult somatic cells". Nature 436 (#7051): 641 
. 
18Comment, “Ethics of therapeutic cloning,” Nature 429 (# 6987): 1 (6 May 2004). 
 
19David Cryanoski, “Korean bioethicists call for inquiry into stem cell work” Nature 429 (#6991): 490 (3 June 2004). 
 
20 The state of knowledge at the time is summarized in Jeffrey L. Platt, Xenotransplantation: Basic Research and Clinical 






billion won ($11 million) for the Hub and make it independent from Seoul National University.  Plans also 
called for establishment of regional affiliates in cooperation with universities in other countries, and 
representatives of the Hub began visiting potential collaborators abroad. 
 
Doubts about the propriety of the oocyte donations continued to swirl, and at about the same time two of 
Hwang’s US-based collaborators, Dr.Gerald Schatten of the University of Pittsburgh (USA) and the Pacific 
Fertility Clinic in San Francisco California, announced they were suspending their collaborations with 
Hwang.  Schatten released a statement saying that the decision was based on concerns about the oocyte 
donations: 
 
Yesterday information came to my attention suggesting that misrepresentations might have 
occurred relating to those oocyte donations. The nature of this information mandates 
confidentiality. I have contacted appropriate academic and regulatory agencies regarding this new 
information and accordingly have suspended my collaborations with Dr. Hwang.21 
 
This was an issue on which he was very sensitive because earlier in his career he had unknowingly worked 
with illegally procured oocytes.22  Commentators soon noted that he was in a good position to know the 
details of the Korean situation because one of the junior researchers later revealed as a donor was working 
in his lab at the time.23 
 
Comments about the situation from European and US scientists in mid-November concentrated on two 
charges: securing egg donations from female researchers within Hwang's laboratory group and incomplete 
information about the risks of follicular aspiration.  Researcher donation was not allowed in mainstream 
laboratories in the United States and elsewhere in the world because of the potential for coercion.  US-
based commentators also recalled that in California, where in vitro fertilization was widely practiced and 
human embryonic stem cell research being advanced under a $3 billion public bond issue, some egg 
donors had died after egg extraction procedures.  
 
Plans to establish the regional affiliates (“sub hubs”) soon ran into problems.  Efforts to establish a sub hub 
In San Francisco were stymied when both the University of California San Francisco (UCSF) and the 
California Institute for Regenerative Medicine (the central coordinator of the State-funded stem cell 
research effort) declined to participate.  Arnold Kriegstein, Head of UCSF’s Institute of Tissue and Stem 
Cell Biology told journalists he had met with Hwang’s representatives but decided not to participate owing 
to concerns about the vagueness of guidelines regarding egg donor recruitment and tracking of research 
materials transferred between labs.  British scientists expressed similar concerns as efforts to establish a 
sub hub at the University of Edinburgh also came to nothing.24 
 
                                                 
21 Quoted in David Glenn, "In South Korea, ethics questions prompt a stem-cell pioneer to resign a top post." The Chronicle of 
Higher Education 52 .16 (Dec 9, 2005) 
 
22Lila Guterman, “A Silent Scientist under Fire” Chronicle of Higher Education, 52.22 (3 Feb 2006), pp. A15-A19 
 
23[note missing at this time] 
 






The controversy intensified in South Korea and elsewhere on November 21st when Dr. Roh Sung-il, Head 
of the fertility clinic at MizMedi Women’s Hospital where many of the oocytes used by Hwang’s team were 
donated, held a news conference and told the assembled journalists that in 2002 he had paid some 20 
women the equivalent of US$1,400 each for donating the eggs used in the research for Hwang's 2004 
embryo cloning paper.  Roh added that payment had become unnecessary later because women were 
willing to donate eggs without compensation after Hwang's work became well-known.  He also insisted that 
Hwang did not know about the early payments.  Roh’s claim that payments were unneeded later appeared 
to be confirmed by news that the non-profit foundation established by Hwang’s supporters the same day to 
secure egg donations had been contacted by 800 women volunteering to become donors before the end of 
the week.   
 
So strong was the support for Hwang that after Munhwa Broadcasting Company showed a segment of its 
news program PD Su-Cheop (Producer's Notebook) discussing the egg donation controversy it was 
accused of being unpatriotic, several advertisers dropped their ads, demonstrators picketed company 
headquarters in Seoul, and the program’s producers of the program were threatened in posts to Internet 
chat boards.  Many Koreans agreed there had been ethical lapses, but felt the controversy and the 
pressure on Hwang reflected efforts to impose Western standards on Korean scientists.  Supporters were 
also quick to point out that payments to donors were not banned in South Korea in 2002-03.  The Bioethics 
and Biosafety Act adopted in late 2003 but not scheduled to take effect until January 2005 closed the door 
indirectly by providing in Article 13, paragraph 1 that embryos can be produced from sperm and oocytes 
only for the purpose of pregnancy and in Article 13, paragraph 3 that “No one shall induce or assist in 
providing or utilizing sperm or oocytes for the purpose of receiving financial reward, property, or any other 
personal benefits.”25  However, the new law also permitted the practice already adopted in many other 
countries of allowing research to be performed with “spare” embryos. 
 
On November 24th Hwang called a press conference to announce his intention to resign as President of the 
World Stem Cell Hub.  He claimed he had rejected proposals that team members donate eggs while 
acknowledged that two members of his team had done so.  He said they had gone ahead and donated 
under false names, he had found out about the donations later, and lied about the source of eggs to protect 
their privacy.  To critics pointing out that he should have been aware that having members of the research 
team act as donors contravened the Helsinki Declaration, Hwang replied that he was unaware of that 
Declaration. 
 
Hwang’s defenders in the government and among the public still felt the charges reflected an unfair 
imposition of foreign standards on Korean researchers.  Health Ministry official Choi Hee-joo was quoted on 
November 24th as saying the women providing eggs for Hwang’s research were motivated by a desire to 
serve science, their actions accorded with Asian ethical conceptions, and neither they nor Hwang’s team 
should be judged by Western standards. 
 
On November 29th, controversy about the propriety of oocyte donations was swamped by claims that 
Hwang’s team had fabricated data in their May 2005 paper claiming to have created patient-specific stem 
cell lines.  Tipped off, Munhwa Broadcasting raised the charges in another segment of PD Su-Cheop.  
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Though this intensified ire against Munhwa, the charges were quickly elaborated by scientists and became 
the subject of worldwide discussion in early December. 
 
In mid-December Seoul National University convened a 9-scientist internal review panel to look into all of 
the charges against Hwang.  Its reports in December and January confirmed the charges that he had faked 
data in the stem cell papers.  They also confirmed irregularities in procurement of oocyte donations.  First, 
the review panel concluded that Hwang’s team had used at least 273 eggs to produce embryos, rather than 
the 185 they reported in the May 2005 Science paper.  It also rejected Hwang's claim that he was unaware 
of egg donations by female researchers on his own team after being informed that he had distributed egg 
donation consent forms to his researchers and even gave one of them a ride to MizMedi Hospital for the 
egg extraction procedure. 
 
In its 2008 report on the controversy, South Korea’s National Bioethics Committee summarized the egg 
donations secured by Hwang’s collaborators as follows:  
 
Location type women donations eggs acquired 
MizMedi Hospital paid 63 75 1336 
Hanna Women’s Clinic in-kind benefit 23 25 313 
MizMedi Hospital volunteer 14 14 182 
Hanna Women’s Clinic volunteer 11 12 230 
Hanyang Univ. Hospital volunteer 8 9 121 
Cheil General Hospital volunteer 1 1 8 
MizMedi Hospital researcher 2 2 31 
Hanyang Univ. Hospital ovary removal 1 114 114 more than 537 
Hanyang Univ. Hospital ovary removal 2 72 113 not reported 
[ovary removal 1 = data in Ryu Young-june 2004 MA Thesis] 
[ovary removal 2 = data from Seoul Prosecutor’s Office for 2002-2003] 
 
The Committee also noted information about side effects.  17.9% of the donors treated at MizMedi Hospital 
suffered OHSS afterward; one paid donor who donated twice needed hospitalization for OHSS both times. 
2 of the 11 volunteer donors at Hanna Women’s Clinic suffered ascites afterward.  No cases of side effects 
were reported from Hanyang University Hospital or Cheil General Hospital.26 
 
III.  Implications 
 
The controversy over methods of recruiting egg donors reflected the combination of global consensus on 
some points and continuing disagreement about others.  Though there is a long history of self-
experimentation – including use of family members and associates – in medical research, today there is 
consensus that students and junior members of research teams should not be used as donors to avoid 
even the suggestion of compulsion. There is still no agreement on whether donors may be paid.  Article 
12(1) of the European Union’s 2004 Tissue and Cells Directive specifies that Member States should 
establish systems of voluntary and unpaid tissue and cell donation but may allow “compensation which is 
strictly limited to making good the expenses and inconveniences related to the donation” and must define 
                                                 






the conditions under which compensation will be paid in national law or regulations. The US National 
Institutes of Health guidelines also recommend against payments to egg donors, though advertisements 
soliciting egg donations to help infertile couples conceive offer significant payments.  In June 2009, the 
New York State (USA) Stem Cell Board, which oversees the state government’s 11 year, $600 million 
dollar program, approved payments of up to $10,000 per donation to overcome the scant supply of suitable 
eggs.  Even proponents of the measure worried that some women would try to donate multiple times for the 
money, and proposed maintaining a general donor register to keep this from happening.27 
 
Hwang’s foreign collaborators were nervous about the egg donor recruitment scandal even before the data 
fabrication charges became public or Hwang confessed he was aware at the time that younger female 
members of his research team had donated eggs.  Hwang’s team could have continued work without the 
foreign collaborators, but their concerns certainly contributed to the World Stem Cell Hub’s difficulty finding 
foreign institutions willing to host regional affiliates in fall 2005. 
 
The data fabrication scandal was a more significant setback to South Korean aspirations than the egg 
donation scandal because the ethical questions involved provoked no disagreement.  While a few 
commentators felt that data fabrication contributed to discrediting science generally, most agreed that the 
scientific requirements for repeatability of results make detection of data fabrication more likely in scientific 
work than in business, journalism, or politics.  As Rob Carlson put it, “There is no other human institution so 
ruthless in chopping out the dead wood.  After all, if you are lying or pulling a fast one, the very last thing 
you want to do is get a bunch of really smart people trying to catch you out, all of whose professional 
standing improves if they do.”  This protective mechanism is very strong in areas of well-established 
science.  In the more rapidly changing, and more exciting, areas of frontier science, where results have not 
yet been tested by others, competition is sharper and there is more room for cheating.  Yet, even there, as 
the Hwang case shows, others’ inability to replicate results will inspire doubts. 
 
Though some observers feared that revelations of Hwang’s data fabrication would discredit science 
generally, the effects were confined mainly to stem cell research, and even there they were relatively short 
lived because of the multiple methods available for acquiring stem cells.  Embryo cloning is very inefficient; 
the first successful animal cloning, of Dolly the sheep, occurred after 276 unsuccessful attempts.  Hwang’s 
data fabrication confirmed other scientists in the view that there were no shortcuts on the horizon, and 
promoted efforts to develop other methods of acquiring stem cells.  While the World Stem Cell Hub folded, 
the Korean Research Institute of Bioscience and Biotechnology (KRIBB) still exists.  Its researchers are 
active in stem cell and other biotechnology research, and KRIBB maintains collaborations with research 
institutions and biotechnology companies around the world.  Korean scientists remain active in the field, 
and the egg donor controversy led to significant improvement in supervision of human subjects research by 
the South Korean Ministry of Health and Institutional Review Boards.  
 
South Korean Legislation, Regulations, and Guidelines in force, 2009 
from International Compilation of Human Research Protections 2009 Edition, p. 67.  
Compiled by the Office for Human Research Protections, U.S. Department of Health and Human Services available 




                                                 







Supervising Agency: Korea Food and Drug Administration (Korean): www.kfda.go.kr/ 
 
Legislation: Pharmaceutical Affairs Act (No. 91235) Articles 10 and 31-34 (2008) 
 
Regulations: Enforcement Rule of Pharmaceutical Affairs Act Articles 22, 31-34 
 
Guidelines: 1.) Korean Good Clinical Practice Public Notification of Food and Drug Administration, No.  
2007-4 (2007) 
 





Supervising Agency: Ministry of Public Administration and Security: http://www.mopas.go.kr 
 





Supervising Agency: Ministry of Health, Welfare, and Family Affairs:  http://english.mw.go.kr/ 
 
Legislation: Bioethics and Safety Act, Chapters 2, 6, 9, 24, 31, 38, and 41 (2005 and 2008 amendments) 
 
Regulations: Enforcement Decree of Bioethics and Safety Act, Articles 2, 3, 13, 14-21, 27, and 28 (2008) 
 
Guidelines: Guidelines for Research Involving Recombinant DNA Molecules (1997) 
 
 
Embryos, Stem Cells, and Cloning 
 
Supervising Agency: Ministry of Health, Welfare, and Family Affairs: http://english.mw.go.kr/ 
 
Legislation: Bioethics and Safety Act, Articles 2, 18-21, 38, 41, and 45 (2005 and 2008 amendments) 
 
Regulations: 1.) Enforcement Decree of Bioethics and Safety Act, Articles 3, 12, and 19-2 (2008);  
 
        2.) Enforcement Regulation of Bioethics and Safety Act, Articles 2, 7, and 13 (2008) 
 
Guidelines: Guideline for Stem Cell Research of Cell by Stem Cell Research Center (2006) 
 
 
<End> 
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